Phenylephrine hydrochloride is a small-molecule alpha-1 adrenergic receptor agonist built on an arylethanolamine core. It's one of the most widely manufactured APIs in the respiratory and cardiovascular categories, though its formulation routes matter more than usual for this molecule — more on that below.

Mechanism of action

As a selective alpha-1 agonist, phenylephrine causes vasoconstriction. Depending on the route of administration, that single mechanism produces very different clinical effects: shrinking swollen nasal mucosa, dilating the pupil, or raising blood pressure during anesthesia.

Where phenylephrine is actually used

  • Topical/nasal decongestant — sprays and drops, where local vasoconstriction reduces nasal mucosal swelling directly at the site of action
  • Ophthalmic solutions — as a mydriatic agent to dilate the pupil for eye examinations and procedures
  • Injectable formulations — used intraoperatively to manage hypotension, particularly during spinal anesthesia
The oral-efficacy questionIn 2023, a U.S. FDA advisory committee reviewed the evidence for oral phenylephrine as an over-the-counter nasal decongestant and concluded it is not effective at approved doses, largely due to extensive first-pass metabolism that leaves very little of the drug reaching systemic circulation when taken by mouth. This finding applies specifically to the oral route — it does not extend to phenylephrine's topical, ophthalmic or injectable uses, where the drug bypasses that metabolic bottleneck and its vasoconstrictive effect is well established.

What this means for formulators

Buyers sourcing phenylephrine API today are, in practice, formulating for the routes where the evidence base is strongest — nasal sprays, ophthalmic drops and injectable solutions — rather than oral tablets aimed at systemic decongestant effect. Confirming intended route early avoids downstream regulatory friction, particularly in markets that have moved to reassess oral cold-and-flu combination products.

Sourcing through NexaImpex

NexaImpex supplies phenylephrine hydrochloride API from WHO-GMP compliant manufacturing partners, with COA, MSDS and TDS documentation prepared against pharmacopoeial specification (USP/EP/IP). We support both bulk orders for established formulations and smaller sample quantities for R&D and stability trials.

Get in touch with our team for current specifications, lead times and documentation for your specific formulation route.